🔥The 9th Round of Easy Loan, Earn $40 Reward is in progress❗️ ⏰ Promotion Period: January 15th - Feburary 15th, 2025 👉 Register now and check more details at gate.io/campaigns/358

In this article for the IAHJ Journal, we explore #OneHealth approaches to integrating human-#veterinary diagnosis at the point-of-care: bit.ly/3kL7Duh

A new variant, B.1.1.529, likely to be designated "Nu", has been detected in #SouthAfrica, Hong Kong and Botswana. #B11519 harbors more than 30 #Spike mutations. However, its #transmissibility and ability to evade #immunity are yet unknown. go.nature.com/3CTnnSc

To support #vaccine and diagnostic R&D, we are developing #Spike and #RBD antigens for the emergent #Omicron variant. If you have any questions or would like to speak with a member of our R&D team, get in touch at: [email protected] bit.ly/3psv8YB

We're thrilled to announce that our SARS-CoV-2 Neutralization Assay Development Kits have been recognised by The Scientist as a Top 10 Innovation of 2021. bit.ly/3lo0TTw

Need a refresher on COVID-19 serology? In this July article written for Clinical Lab Products Magazine, Dr Andy Lane provides an overview of the role of #serology in tracking #COVID19 mutations. bit.ly/2WAVtLg #Vaccines #Diagnostics #Omicron #COVID

The Native Antigen Company is now taking orders for SARS-CoV-2 #Omicron (B.1.1.529) whole Spike, S1 and RBD antigens. bit.ly/3m0bkx8 For more information on these products, click the link below or get in touch at: [email protected]

Take a look at our open positions in Marketing, Sales, Finance, New Product Development, and Operations! Apply now: hubs.ly/Q0115XT10

LGC Clinical Diagnostics will be attending MEDLAB Middle East 24-27 January. Visit us at booth Z6. D48. To learn more, or to schedule time with one of our onsite representatives, click here: hubs.ly/Q011p76T0

The Native Antigen Company offers a growing range of SARS-CoV-2 #Omicron (B.1.1.529) antigens, now including whole Spike, S1 and RBD. bit.ly/3m0bkx8 For more information on these products, click the link below or get in touch at: [email protected]

A structural analysis of the #SARSCoV2 #Omicron Spike trimer reveals that many of its mutations are present at the protein surface, where they confer a near 10-fold increase in #ACE2 binding affinity while decreasing affinity to many antibodies. bit.ly/3qT9CiI

To support #norovirus research and development, The Native Antigen Company offers norovirus-like particles for six new #genotypes, four of which are unique. For more information, click the link below or get in touch at: [email protected] bit.ly/33v2iSa

Discover the story of the production of the first commercially available SARS-CoV-2 spike proteins and the fortuitous circumstances that led to their creation in this interview feature with James Shore of Native Antigen. bit.ly/3K3aw4T

In BioPharm International's latest industry Q&A on #COVID19 vaccines, we explain the role of variant-specific reagents in vaccine testing and how they can be developed at speed. bit.ly/3rr7Rcz

The Native Antigen Company offers new #humanized antibodies to SARS-CoV-2, that show differential affinities and neutralising ability to variants. For more information on these products, click the link below or get in touch at: [email protected] bit.ly/3Ih6tju

In European Biopharmaceutical Review's latest issue, we discuss the emergence of the flaviviruses and challenges in developing effective serological #diagnostics for their detection. To read the full article, see pages 32 - 35. en.calameo.com/read/006113385…

The Native Antigen Company now offers a new range of services for virological research and the development of diagnostics, therapeutics, and vaccines. To find out more, click the link below or get in touch at: [email protected] bit.ly/3rOjyKB

To support #vaccine development for the upcoming 2022 Southern Hemisphere flu season, The Native Antigen Company now offers formulation-specific HA and NA #antigens. #flu #influenza #reagents #IVD #Vaccines bit.ly/3bl2Mvs

James Shore at Native Antigen explores the challenges of flaviviruses and the urgent need for more accurate data. Read the full article (and many more) 👇 en.calameo.com/read/006113385…

In this editorial for Biocompare, we comment on the role of reagents in assessing the efficacy of vaccines, and their broad application in supporting the development of novel technologies. #Vaccines #mRNA #Pharma #Biotech #Antibodies #Antigen #Serology bit.ly/3p8aksg

The WHO last week announced its #vaccine recommendations for the 2022/2023 Northern Hemisphere #flu season. The Native Antigen Company offers HA and NA #antigens for many of these viruses, with the remainder anticipated to be available in early April. bit.ly/3bl2Mvs